Lurasidone HCl
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Male, Healthy Normal Subjects
Conditions
Male, Healthy Normal Subjects
Trial Timeline
Aug 1, 2008 → Aug 1, 2008
NCT ID
NCT01082276About Lurasidone HCl
Lurasidone HCl is a phase 1 stage product being developed by Sumitomo Pharma for Male, Healthy Normal Subjects. The current trial status is completed. This product is registered under clinical trial identifier NCT01082276. Target conditions include Male, Healthy Normal Subjects.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04432688 | Pre-clinical | Completed |
| NCT01143090 | Phase 3 | Completed |
| NCT01143077 | Phase 3 | Completed |
| NCT01074632 | Phase 1 | Completed |
| NCT01082263 | Phase 1 | Completed |
| NCT01074073 | Phase 1 | Completed |
| NCT01082276 | Phase 1 | Completed |
| NCT01082250 | Phase 1 | Completed |
| NCT00549718 | Phase 3 | Completed |
Competing Products
20 competing products in Male, Healthy Normal Subjects
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ENZ215 + EU Sourced Prolia + US Sourced Prolia | Alkem Laboratories | Phase 1 | 33 |
| Fulvestrant + Abemaciclib | Eli Lilly | Phase 2 | 52 |
| Gemcitabine + liposomal doxorubicin | Eli Lilly | Phase 3 | 77 |
| [14C]-LY3549492 + LY3549492 + [14C]-LY3549492 | Eli Lilly | Phase 1 | 33 |
| CT-P41 + EU-approved Prolia | Celltrion | Phase 1 | 33 |
| CT-P55 + US-licensed Cosentyx + EU-approved Cosentyx | Celltrion | Phase 1 | 33 |
| CT-P52 | Celltrion | Phase 1 | 33 |
| CT-P43 + CT-P43 | Celltrion | Phase 1 | 33 |
| Telmisartan + Amlodipine + Rosuvastatin | Yuhan | Phase 1 | 33 |
| ASP3325 + Placebo | Astellas Pharma | Phase 1 | 33 |
| TRK-100STP | Astellas Pharma | Phase 1 | 33 |
| Ensitrelvir | Shionogi | Phase 1 | 33 |
| E6011 + E6011 Matching Placebo | Eisai | Phase 1 | 33 |
| E6130 + Placebo | Eisai | Phase 1 | 33 |
| Eribulin Injection [Halaven] + Paclitaxel injection | Eisai | Approved | 85 |
| E3112 | Eisai | Phase 1 | 33 |
| E2022 Tape Formulation | Eisai | Phase 1 | 33 |
| Placebo + E3112 | Eisai | Phase 1 | 33 |
| [14C]-E6007 | Eisai | Phase 1 | 33 |
| E2022 + E2022 + E2022 + E2022 + E2022 | Eisai | Phase 1 | 33 |